Anti-HLA-C Autoantibodies and Platelet Transfusion Refractoriness
Author Information
Author(s): Xunhua Li, Qi Liu, Jingjie Dong, Yaonan Hong, Chuanao Xin, Junfeng Guo, Shan Liu, Peicheng Wang, Zexing Sun, Yingying Shen, Xiawan Yang, Hangchao Li, Yiping Shen, Jianping Shen, Baodong Ye, Yuhong Zhou, Tonglin Hu, Dijiong Wu
Primary Institution: The First Affiliated Hospital of Zhejiang Chinese Medical University
Hypothesis
This study aims to investigate the incidence and risk factors for primary and persistent platelet transfusion refractoriness (P/P PTR) in patients with hematologic disorders.
Conclusion
The study highlights the significance of anti-HLA-C autoantibodies as an independent risk factor for P/P PTR in hematological patients, suggesting that rituximab may be a useful treatment.
Supporting Evidence
- 28.95% of patients experienced platelet transfusion refractoriness (PTR), with 63.63% classified as primary and persistent (P/P) PTR.
- Anti-HLA-C autoantibody was identified as an independent risk factor for P/P PTR.
- Application of rituximab may be practical in managing P/P PTR with HLA-C autoantibodies.
Takeaway
Some patients have trouble getting better after platelet transfusions because their bodies make antibodies against the platelets. This study found that a specific type of antibody, called anti-HLA-C, can make this problem worse.
Methodology
The study reviewed clinical data from patients with hematologic disorders who underwent HLA high-resolution genotyping and antibody testing between January 2019 and March 2023.
Potential Biases
The study may be biased due to the retrospective design and the limited number of patients with anti-HLA-C autoantibodies.
Limitations
The study is retrospective with a limited sample size of patients with anti-HLA-C autoantibodies and did not analyze the influence of the combination of anti-HLA antibodies.
Participant Demographics
{"median_age":40,"age_range":"14-80","gender_distribution":{"male":46,"female":68},"disease_distribution":{"aplasitic_anemia":75,"leukemia":25,"myelodysplastic_syndrome":10,"other":4}}
Statistical Information
P-Value
{"anti_HLA_I":0.019,"anti_HLA_C":0.039}
Confidence Interval
{"anti_HLA_I":"1.184–6.453","anti_HLA_C":"1.130–8.894"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website